Ichnos CEO On The ‘ASH Of Bispecifics’, Progress With Trispecific
Executive Summary
Ichnos’ CEO Dr Cyril Konto highlights promising early data presented at ASH for the firm’s trispecific antibody in multiple myeloma versus teclistamab and alnuctamab. He also outlines why the US-based spin out of Glenmark isn’t considering the special purpose acquisition company alternative to the conventional IPO.
You may also be interested in...
What Pharma CEOs, PEs Want To Move The Innovation Needle In India
Leaders of biopharma and private equity firms at a recent conference sought a robust domestic market and reimbursement mechanism to propel the innovation ecosystem in India, drawing parallels with the framework that aided China's ascent in the R&D value chain. Alongside, regulatory reform is also pivotal, they stressed.
What Pharma CEOs, PEs Want To Move The Innovation Needle In India
Leaders of biopharma and private equity firms at a recent conference sought a robust domestic market and reimbursement mechanism to propel the innovation ecosystem in India, drawing parallels with the framework that aided China's ascent in the R&D value chain. Alongside, regulatory reform is also pivotal, they stressed.
Keeping Track: RSV Vaccine Race Heats Up Between Pfizer And GSK; Another J&J Bispecific For Myeloma
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.